Most Recent
Not to be outdone by other class action firms vying to recruit AMP shareholders for a $2 billion class action, Slater & Gordon announced Friday it would offer investors "the most competitive funding package of all".
Boutique law firm Phi Finney McDonald is investigating a potential shareholder class action against BHP Billiton over the fatal Samarco disaster in Brazil, which saw the market value of the mining giant plummet by $25 billion.
Beleaguered financial institution AMP is facing yet another shareholder class action with Shine Lawyers joining three other law firms in what is shaping up to be a beauty pageant of class actions.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company's founder and her lawyers from DLA Piper.
The ACCC won its case against Sydney-based Unique International College on a "paucity of material", the Full Federal Court has heard in an appeal of a ruling that found the vocational trainer exploited disadvantaged people and violated the Australian Consumer Law.
Optus was ordered Wednesday to temporarily pull an ad that Telstra alleges makes a false and damaging claim about the superiority of Optus' mobile network.
The Federal Court has ordered appliance and furniture leasing company Radio Rentals to pay a $2 million penalty for failing to verify consumers' financial situations before signing them up for leases.
The Full Federal Court on Tuesday dismissed an appeal by aviation services company Aerocare of a ruling rejecting an enterprise agreement the Transport Workers Union called "substandard".
The financing arrangement underwriting Quinn Emanuel's shareholder class action against AMP, which will earn its partner Burford Capital a record low 10 percent of any recovery, sets a new standard in class action litigation funding, and is expected to spark greater price competition in the industry.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to "tens of millions of dollars" in losses.